Description
The BB9 monoclonal antibody specifically binds Angiotensin-converting enzyme (ACE) which is also known as Dipeptidyl carboxypeptidase 1 (DCP1) or CD143. CD143 is a type I transmembrane glycoprotein that functions as a zinc metallopeptidase involved with the metabolism of angiotensin, bradykinin, and other oligopeptides. It is expressed on primitive hematopoietic progenitor cells (HPC). BB9 reacts with stromal cells, a minor subset of human bone marrow cells; it does not react with peripheral blood leucocytes. BB9 recognizes a subset of CD34+CD90+ cells that demonstrate low or absent expression of CD38, low retention of Rhodamine 123 and are Ki-67-negative. CD34+BB9+ cells are able to sustain hematopoiesis in pre-CFU culture stimulated with IL-3, IL-6, G-CSF, and SCF. BB9 also reacts with a subset of CD34+ cells from mobilized peripheral blood. This antibody was generated using human bone marrow-derived stromal cells as immunogen.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794 or 566349). When setting up compensation, it is recommended to compare spillover values obtained from cells and BD™ CompBeads to ensure that beads will provide sufficiently accurate spillover values. For optimal results, it is recommended to perform two washes after staining with antibodies. Cells may be prepared, stained with antibodies and washed twice with wash buffer per established protocols for immunofluorescent staining prior to acquisition on a flow cytometer. Performing fewer than the recommended wash steps may lead to increased spread of the negative population.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BB700 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
9. BD Horizon Brilliant Blue 700 is covered by one or more of the following US patents: 8,455,613 and 8,575,303.
10. Cy is a trademark of GE Healthcare.
